Abstract
Graft versus host disease (GVHD remains the major obstacle to the application of bone marrow transplantation across HLA barriers. Recent advances in our understanding of GVHD pathophysiology have resulted in the evaluation in animal models and in clinical trials of some novel approaches to avoiding and treating GVHD. Continued advances in our knowledge are likely to result in the clinical application of biological therapies to maximize graft versus leukemia effects and alloengraftment, while avoiding GVHD.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
